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Abstract
Background: Chemokine SDF1α and its unique receptor CXCR4 have been implicated in organ-specific metastases of 
many cancers including breast cancer. Hypoxia is a common feature of solid tumors and is associated with their 
malignant phenotype. We hypothesized that hypoxia would upregulate CXCR4 expression and lead to increased 
chemotactic responsiveness to its specific ligand SDF1α.
Methods: Three breast cancer cell lines MDA-MB-231, MCF7 and 4T1 were subjected to 48 hrs of hypoxia or normoxia. 
Cell surface receptor expression was evaluated using flow cytometry. An extracellular matrix invasion assay and 
microporous migration assay was used to assess chemotactic response and metastatic ability.
Results: CXCR4 surface expression was significantly increased in the two human breast cancer cell lines, MDA-MB-231 
and MCF7, following exposure to hypoxia. This upregulation of CXCR4 cell surface expression corresponded to a 
significant increase in migration and invasion in response to SDF1-α in vitro. The increase in metastatic potential of both 
the normoxic and the hypoxic treated breast cancer cell lines was attenuated by neutralization of CXCR4 with a CXCR4 
neutralizing mAb, MAB172 or a CXCR4 antagonist, AMD3100, showing the relationship between CXCR4 overexpression 
and increased chemotactic responsiveness.
Conclusions: CXCR4 expression can be modulated by the tissue microenvironment such as hypoxia. Upregulation of 
CXCR4 is associated with increased migratory and invasive potential and this effect can be abrogated by CXCR4 
inhibition. Chemokine receptor CXCR4 is a potential therapeutic target in the adjuvant treatment of breast cancer.
Background
Breast cancer is the most common malignancy in women,
characterized by a distinct pattern of metastasis involving
regional lymph nodes, bone marrow, lung and liver.
About 1 million cases of breast cancer are detected each
year in the world [1]. Although early stage breast cancers
are not life threatening, development of metastatic breast
cancer is responsible for the majority of cancer-related
death. Metastasis is the result of several sequential steps
and represents a highly organized, non-random and
organ-selective process [2]. A wide number of molecules
such as cytokines, chemokines and their receptors, and
growth factors have been implicated to be responsible for
the metastatic property of breast cancer cells [3-9]. How-
ever, the precise cellular and molecular mechanisms that
determine primary tumour growth and the directional
migration and invasion of tumour cells into the second-
ary organs have yet to be established.
Hypoxia is the result of an imbalance between oxygen
delivery and oxygen consumption resulting in the reduc-
tion of oxygen tension below the normal level for a spe-
cific tissue [10]. Oxygen tensions have been measured in
several cancer types, using eppendorf histography elec-
trodes showing a range of values between 0 and 20
mmHg in tumour tissues, which were significantly lower
than those of the adjacent tissue (24 - 66 mmHg) [11-13].
In breast cancers of stages T1b-T4, measurement of oxy-
gen tension revealed a median pO2 of 28 mmHg com-
pared with 65 mmHg in normal breast tissue [14].
Hypoxia in solid tumours like breast cancer is felt to be
due to the tumour outgrowing the existing vasculature.
Under these hypoxic conditions, numerous cellular
mechanisms are compromised and an adaptive response
occurs which allows cancer cells to adapt to this hostile
environment. This renders them more resistant and with
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improved ability to survive and even proliferate, promot-
ing tumour development [15].
Hypoxia-inducible factor (HIF) is a transcription factor
that responds to changes in available oxygen in the cellu-
lar environment [16]. HIF consists of two subunits, a α
subunit whose level increases during hypoxia and a β sub-
unit that is constitutively expressed [17]. Although HIF-
1α expression may also be influenced by other pathways,
a significant correlation between oxygen tension and
HIF-1α has been reported in cervical cancer, suggesting
t h a t  H I F - 1 α  m i g h t  b e  u s e d  a s  a  s u r r o g a t e  f o r  t u m o u r
hypoxia [18]. By using HIF-1α as a marker for hypoxia,
approximately 25-40% of all invasive breast cancer sam-
ples are hypoxic; the frequency of HIF-1α-positive cells
increases in parallel with increasing pathologic stage and
is associated with a poor prognosis [19-21].
Clear-cell renal cell carcinoma (ccRCC), the most fre-
quent subtype of renal cancer, is characterized by inacti-
vation of the von Hippel-Lindau (VHL) tumour
suppressor gene in about 70% of the tumours. The VHL
protein binds to HIF and targets it for ubiquitination and
degradation. Therefore, loss of VHL in these tumours
leads to persistently elevated levels of HIF expression
[22]. Loss of VHL function in ccRCC also results in
strongly enhanced transcription of the HIF-inducible, G-
protein-coupled, CXC motif, chemokine receptor 4
(CXCR4), and its cognate, stromal derived factor1α
(SDF1α) [22,23].
CXCR4 is a G-protein coupled receptor that is
expressed constitutively in a wide variety of normal tis-
sues, including lymphatic tissues, thymus, brain, spleen,
stomach, and small intestine [24]. This receptor is also
expressed in normal stem cells from a variety of tissues,
including mammary stem cells [25]. The fact that CXCR4
is present in normal mammary stem cells suggests that
this molecule may be essential for stem cells that appear
to be progenitors of breast carcinoma [26]. Signalling
through CXCR4 activates a number of downstream effec-
tor molecules, including molecules that regulate key pro-
cesses such as cell cycle control and apoptosis. The
chemokine SDF1α is also expressed constitutively in a
variety of tissues, including lung, liver, lymph nodes, bone
marrow, and adrenal glands [24,27,28]. Of particular rele-
vance to breast cancer, many of the organs with highest
expression levels of SDF1α correlate with common sites
of metastatic breast cancer, such as bone, liver lung and
lymph nodes. Muller et al [9] investigated functions of
chemokines and chemokine receptors in breast cancer.
These investigators found that high levels of SDF1α are
produced in many organs and tissues commonly affected
by metastatic breast cancer, while CXCR4 appears to be
expressed in human breast cancer cells and metastatic
lesions. CXCR4 signalling in response to SDF1α induces
chemotaxis and migration of breast cancer cells. In a
mouse model of breast cancer, neutralizing antibodies to
CXCR4 significantly limited metastases to lymph nodes
and lung [9]. Their data were the first to identify a key
function for SDF1α-CXCR4 in metastatic breast cancer.
Our hypothesis was that the hypoxia commonly found in
primary breast cancers would induce an increased
expression of CXCR4, and that this increase in CXCR4
expression would increase breast cancer cells metastatic
ability.
Methods
Cell lines and cultures
MCF7 and MDA-MB-231, two human breast cancer cell
lines, and 4T1, a murine breast cancer cell line, were
maintained in Dulbecco-modified Eagle medium
(DMEM), supplemented with 10% fetal calf serum, peni-
cillin (100 units/ml), streptomycin (100 μg/ml), and glu-
tamine (2 mM). Cells were grown at 37°C in a humidified
atmosphere with 5% CO2. The cells in hypoxic experi-
ments were exposed to 2% O2 with 5% CO2 at 37°C for 48
hrs. All culture medium and reagents for cell cultures
were purchased from Invitrogen Life Technologies (Pais-
ley, Scotland, UK).
Cell surface expression of CXCR4
After being cultured in either normoxic condition or
hypoxic condition for 48 hrs, cells were stained with PE-
conjugated anti-CXCR4 mAb (FAB170P, Clone 12G5)
(R&D Systems, Minneapolis, MN). PE-conjugated mouse
IgG2a isotype-matched mAb (IC003P, R&D Systems) was
used as the negative control. FACScan analysis was per-
formed from at least 5,000 events for detecting cell sur-
face expression of CXCR4 using CellQuest software (BD
Biosciences, San Jose, CA).
Tumour cell migration and invasion assay
Tumour cell migration through a microporous mem-
brane and invasion through an extracellular matrix were
assessed based on the Boyden chamber principle using
the fluorescent CyQuant GR dye (Chemicon, Temecula,
CA). Cells were incubated with culture medium as the
control, 10 μg/ml control IgG2b mAb (MAB004, R&D Sys-
tems), 10 μg/ml CXCR4 blocking mAb (MAB172, R&D
Systems), or 100 nM CXCR4 antagonist AMD3100
(Sigma-Aldrich, St. Louise, MO) for 1 hr, and then plated
onto the top chamber. Culture medium containing 100
ng/ml of either recombinant mouse SDF1α (460-SD,
R&D Systems) or recombinant human SDF1α (350-NS,
R&D Systems) was added into the lower chamber. The
plate was incubated at 37°C, 5% CO2 for 18 hrs. The
migrated or invaded cells were dislodged from the under-
side of the chamber using a detachment solution. A lysisCronin et al. BMC Cancer 2010, 10:225
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buffer and dye solution was added and the plate was read
with a fluorescence plate reader using a 480/520 nm filter
set (Thermo Labsystems, Cheshire, England, UK).
Cell viability
Cell viability was assessed by measuring the ability of cells
to metabolize MTT (Sigma-Aldrich), a water-soluble tet-
razolium salt, into a water insoluble formazan product. In
brief, tumour cells (5 × 103/well) were plated into 96-well
plates at 37°C, 5% CO2 for 12 hrs. Cells were then treated
with culture medium, 10 μg/ml control IgG2b  mAb
(MAB004, R&D Systems), 10 μg/ml CXCR4 blocking
mAb (MAB172, R&D Systems), or 100 nM AMD3100
(Sigma-Aldrich) at varying doses. After 24 hrs, 50 μl of 1
mg/ml of MTT solution was added to each well and incu-
bated for 3 hrs. The supernatant was then gently removed
and 100 μl DMSO (Sigma-Aldrich) added to each well.
The OD value in each well was measured with a micro-
plate reader (Dynatech Laboratories, Chantilly, VA) at
absorption wavelength of 570 nm with a reference wave-
length of 650 nm.
Statistical analysis
All data are presented as the mean ± SD. The significance
of the difference was analysed with a two-sided Student's
t test, and a p value < 0.05 was considered statistically sig-
nificant.
Results
Hypoxia facilitates breast cancer cell migration and 
invasion
To examine the effect of hypoxia on breast cancer cell
metastatic ability, two human breast cancer cell lines
MCF7 and MDA-MB-231, and one murine breast cancer
cell line 4T1 were exposed to either normoxia or hypoxia
for 48 hrs. Breast cancer cell migration through a microp-
orous membrane and invasion through an extracellular
matrix were assessed under both normoxic and hypoxic
conditions. It was observed that exposure of these three
breast cancer cell lines to hypoxic conditions resulted in
significantly increased migration (Figure 1A) and inva-
sion (Figure 1B) in vitro.
Following confirmation of increased metastatic ability
i n  h y p o x i a - t r e a t e d  b r e a s t  c a n c e r  c e l l s ,  w e  w i s h e d  t o
investigate whether CXCR4 played a role in this
increased capacity, as CXCR4 has been implicated in
breast cancer metastases and linked to tumours with
increased levels of HIF1α (a surrogate of hypoxia). We
again treated cells to the same hypoxic and normoxic
conditions and assessed cell surface expression of CXCR4
by FACScan analysis. Exposure of two human breast can-
cer cell lines MDA-MB 231 and MCF7 to hypoxia led to a
statistically significant increase in cell surface expression
of CXCR4 by 27.5% (p < 0.05) and 67.5% (p < 0.05),
respectively, when compared to cells exposed to nor-
moxia (Figure 2A-C).
Blocking CXCR4 attenuates breast cancer cell migration 
and invasion
To determine if the increased metastatic potential seen
following hypoxia treatment was associated with the
increased cell surface expression of CXCR4, we repeated
the migration and invasion experiments in two human
breast cancer cells lines, MDA-MB 231 and MCF7. Cells
were exposed to either 48 hrs of the same normoxic or
hypoxic conditions. Before assessment of cell migration
and invasion, both MDA-MB-231 and MCF7 cells were
incubated with either a CXCR4 blocking mAb, MAB172
(10 μg/ml), or a CXCR4 antagonist, AMD3100 (100 nM)
for 1 hr. Culture medium and control IgG2b  mAb,
MAB004 (10 μg/ml) were used as the control. It was
observed that attenuation of CXCR4 with either the
blocking mAb, MAB172 or the antagonist, AMD3100 led
to statistically significant attenuation of breast cancer cell
Figure 1 Migration of breast cancer cells through a microporus 
membrane (A) and invasion through an extracellular matrix (B) in 
response to SDF1α in normoxia and hypoxia conditions. Three cell 
lines MDA-MB-231, MCF7, and 4T1 cells were exposed to either nor-
moxia or hypoxia (2% O2 with 5% CO2) for 48 hrs. Cell migration and in-
vasion were assessed as described in the Methods and expressed as 
relative fluorescence units (RFU). Data are presented as the mean ± SD 
of duplicate samples and are representative of three independent ex-
periments. *p < 0.05 versus normoxia-treated cells.Cronin et al. BMC Cancer 2010, 10:225
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migration in response to SDF1α in MCF7 (Figure 3A) and
MDA-MB-231 (data not shown) cells. This effect was not
seen with the isotype control mAb.
Similarly, CXCR4 inhibition with the CXCR4 blocking
mAb led to statistically significant attenuation of cell
invasion through an extracellular matrix in response to
SDF1α observed in hypoxia-treated MCF7 (Figure 3B)
and MDA-MB-231 (data not shown) cells. The CXCR4
antagonist, AMD3100 was also observed to have a similar
effect as the CXCR4 blocking mAb with attenuation of
extracellular matrix invasion of hypoxia-treated MCF7
(Figure 3B) and MDA-MB-231 (data not shown) cells.
To assure that the effects of CXCR4 attenuation on
breast cancer cell migration and invasion was not due to
decreased cell viability resulted from the treatment with
the CXCR4 blocking mAb or the CXCR4 antagonist; we
assessed the effect of CXCR4 blockade on cell viability
with an MTT assay. AMD3100 was tested at varying con-
centrations from 0.5 to 100 nM and the blocking mAb
was tested at concentrations from 2.5 to 20 μg/ml. As
shown in Figure 4A and 4B, treatment of breast cancer
cells with AMD3100, the blocking mAb or the isotype
control mAb did not significantly affect cell viability in
vitro. Lower doses of CXCR4 blockade seemed to have a
mild proliferative effect and this was significant at a dose
of 5 nM of AMD and at a dose of 2.5 μg/ml of the block-
ing mAb. The higher dose of 20 μg/ml of the mAb did
show a significant negative effect on cell viability, but the
treatment dose of 10 μg/ml did not.
Figure 2 Cell surface expression of CXCR4 in normoxia and hypoxia treated MDA-MB-231 (A) and MCF7 (B) cells. Human breast cancer cell 
lines, MDA-MB-231 and MCF7 cells were exposed to either normoxia or hypoxia (2% O2 with 5% CO2) for 48 hrs. Cell surface expression of CXCR4 on 
breast cancer cells was assessed by FACScan analysis, and expressed as mean channel fluorescence (MCF). (A-B) Results shown represent one exper-
iment from a total of three independent experiments. The grey filled indicates CXCR4 expression on normoxia-treated cells, whereas the grey line 
indicates CXCR4 expression on hypoxia-treated cells. (C) Data are expressed as the mean ± SD of three separate experiments. *p < 0.05 versus nor-
moxia-treated cells.Cronin et al. BMC Cancer 2010, 10:225
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Discussion
It has been proposed that molecules regulating the meta-
static dissemination of tumour cells in an organ specific
manner would need to fulfil certain criteria [2,29]. They
would have to be constitutively expressed in the target
organs of metastasis. Adhesion of the circulating tumour
cells to the endothelium and their transendothelial
migration would need to be promoted. These molecules
would need to be capable of mediating the invasion of
tumour cells into tissues that would provide supportive
microenvironments. Lastly, this process would require
the expression of a distinct receptor repertoire by the tar-
get cells, depending on their metastatic profile. Given
their well-established roles in leukocyte trafficking and
homeostasis, chemokines are perfectly positioned to fulfil
these criteria [30-37].
CXCR4 with its unique ligand SDF1α has been and
continues to be a source of investigation into the organ
specific metastases of several types of cancer including
breast cancer. Muller et al [9] were the first to investigate
the functions of chemokines and chemokine receptors in
breast cancer. They found that high levels of SDF1α are
produced in many organs and tissues commonly affected
by metastatic breast cancer, while CXCR4 appears to be
expressed in human breast cancer cells and metastatic
lesions. CXCR4 signalling in response to SDF1α was
found to induce chemotaxis and migration of breast can-
cer cells. These data were the first to elucidate key roles
for the CXCR4-SDF1α receptor-ligand axis in metastatic
breast cancer. The hypothesis now proposed holds that
organ-specific attractant molecules such as SDF1α stimu-
late the migrating tumour cells to invade the walls in
blood vessels and enter the target organs. This theory is
widely known as "chemoattraction" theory which is simi-
lar with Paget's original paper looking at the site specific
Figure 3 The effect of CXCR4 inhibition on cell migration (A) and 
invasion (B) in hypoxia-treated breast cancer cells. Human breast 
cancer cell line, MCF7 cells were exposed to hypoxia (2% O2 with 5% 
CO2) for 48 hrs, and further incubated with either a CXCR4 blocking 
mAb, MAB172 (mAB, 10 μg/ml), or a CXCR4 antagonist, AMD3100 
(AMD, 100 nM) for 1 hr. Culture medium (CM) and control IgG2b mAb, 
MAB004 (IgG, 10 μg/ml) were used as the control. Cell migration and 
invasion were assessed as described in the Methods and expressed as 
(relative fluorescence units RFU). Data are presented as the mean ± SD 
of duplicate samples and are representative of three independent ex-
periments. *p < 0.05 versus CM or IgG treated cells.
Figure 4 Cell viability of MCF7 breast cancer cells following treat-
ment with either AMD3100 or the CXCR4 blocking mAb. Cells were 
treated with (A) CXCR4 antagonist AMD3100 (0.5 - 100 nM) and (B) the 
blocking mAb, MAB172 (2.5 - 20 μg/ml) for 24 hrs at 5% CO2 at 37°C. 
Control IgG2b mAb, MAB004 (10 μg/ml) was used as the control. Data 
are expressed as the mean ± SD of duplicate samples and are repre-
sentative of three independent experiments. *p < 0.05 versus (A) cul-
ture medium (CM) or (B) control mAb (IgG) treated cells.Cronin et al. BMC Cancer 2010, 10:225
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pattern of breast cancer metastases proposing "seed and
soil theory" [38].
Hypoxia is a primary factor in the pathology of many
disease states, including solid tumours [12-14]. In this
paper we propose that in solid tumours such as breast
cancer, in addition to genetic alterations such as muta-
tions of VHL [22], PTEN [39], or p53 [40] that are associ-
ated with increased levels of HIF1 transcriptional activity,
tumour microenvironmental hypoxia may increase
CXCR4 expression and thus the metastatic potential of
cancer cells. The results in this paper support other find-
ings in the literature that suggest that hypoxia plays a key
role in CXCR4 expression. Schioppa T et al [41] also
looked at the role of oxygen levels on CXCR4 expression.
They found that low oxygen concentration induced high
expression of SDF1α and CXCR4, in different cell types
(monocytes, monocyte-derived macrophages, tumour-
associated macrophages, endothelial cells, and cancer
cells). Our data support these findings showing that
breast cancer cells are sensitive to the microenvironment,
in particular oxygen levels which can lead to upregulation
of CXCR4 cell surface expression.
We further demonstrated that upregulation of CXCR4
in breast cancer cells secondary to hypoxia is associated
with increased chemotactic ability and metastatic poten-
tial, and that this effect can be abrogated by CXCR4
attenuation. This finding may indicate a potential thera-
peutic role for CXCR4 inhibition. Certainly, in vivo stud-
ies [9,42] have confirmed this theory with CXCR4
inhibition in mouse models of cancer showing decreased
metastases. Immunhistochemistry studies of primary
breast tumours have also demonstrated a relationship
between CXCR4 expression and metastases [43-47].
Tumours with high expression of CXCR4 are associated
with more aggressive phenotypes showing increased rates
of distant metastases and poorer clinical outcome.
Organ-specific metastases to liver [46] and bone marrow
[47] have been shown again consistent with the
"chemoattraction" theory. Further reason to believe that
interference with the CXCR4-SDF1α receptor-ligand axis
could be of potential therapeutic benefit in the treatment
or prevention of breast cancer metastases.
The perioperative period may afford a window of
opportunity for treatment using interference of the
CXCR4-SDF1α axis. There are many factors during the
perioperative period that are thought to affect tumour
development [48]. One of these is the possibility of
increased circulating tumour cells postoperatively
[49,50]. Therefore, we would propose that treatment with
CXCR4 antagonists such as AMD3100 in the periopera-
tive period would prevent the migration and invasion of
C X C R 4  e x p r e s s i n g  b r e a s t  c a n c e r  c e l l s  i n t o  o r g a n s  o f
metastases that are rich in SDF1α. AMD3100 is safe, in
December 2008, Plerixafor, the new trade name for
AMD3100, was approved by the FDA of United States for
use in patients with non-Hodgkin's lymphoma and multi-
ple myeloma [51]. It is used in combination with granulo-
cyte colony-stimulating factor in these patients to
mobilize haematopoietic stem cells to the peripheral
blood for collection and subsequent autologous trans-
plantation.
Conclusion
In summary, CXCR4-SDF1α receptor-ligand axis plays an
important role in the metastatic ability of breast cancer
cells. CXCR4 is expressed on breast cancer cells and
exposure to hypoxia upregulated this expression. From
the literature we know that hypoxic breast cancer pri-
mary tumours correlate with later stage tumours and
metastases and are associated with patients of poor prog-
nosis. We propose that one of the mechanisms underly-
ing this increased metastatic ability and poorer prognosis
is that tumour hypoxia through upregulation of CXCR4
cell surface expression leads to increased metastatic
potential of breast cancer cells. We would also suggest
that further work in this area should look at utilising the
perioperative window as the possible timing of interfer-
ence in this axis as a potential metastases preventative
strategy.
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